A post-hoc safety analysis of the phase 3 OptiTROP-Breast01 trial reported that the key adverse events associated with sacituzumab tirumotecan in metastatic triple-negative breast cancer were mainly concentrated in the first two cycles. The company said these events were largely reversible with dose modification and supportive care. The analysis is intended to add granularity to the adverse-event timeline rather than change efficacy conclusions. For clinicians, the actionable element is the implied manageability pattern—early monitoring needs may be higher, followed by improved tolerability after the initial exposure window. As a post-hoc dataset, it may be subject to limitations typical of analyses not predefined for this time-window framing, but it directly informs day-to-day dosing and supportive care planning.